Skip to main content
OpenTrials
Completed

NCT Number: NCT04260152

Evaluation of Geistlich Fibro-Gide® + CAF in Comparison to CTG + CAF for the Treatment of Recession Defects at 6 Months

This double blind, randomized, split mouth study evaluates the non-inferiority of Geistlich Fibro-Gide® in comparison to connective tissue graft for the treatment of Miller Class I or II recession defects at 6 months post treatment.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Seven Lakes Periodontitis, Fenton, Michigan, United States

Loading trial locations.

About this study

This double blind, randomized, split mouth study evaluates the non-inferiority of Geistlich Fibro-Gide® in comparison to connective tissue graft for the treatment of Miller Class I or II recession defects at 6 months post treatment.

A total sample size of 30 subjects (n=30) will be evaluated at 3 centers with 4 investigators. Power analysis based on 80% power and past McGuire/ Scheyer matched-pair defect recession coverage studies, with one-sided confidence interval 0.025, indicates that in order to detect a 12% difference in root coverage with ± 15% standard deviation a patient sample of 25 should be used . Given the multi-center nature of this study and the intention to follow patients long-term, with normal attrition, 30 subjects will ensure adequate long-term follow-up and provide a "power buffer" for any outcome differences that might be seen between centers.

30 Patients with Miller Class I or II recession defects on bilateral sites will be treated randomly with coronally advanced flap (CAF) in combination with either Geistlich Fibro-Gide (GFG =Test) on one side, and Connective Tissue Graft (CTG = Control) on the contralateral side of the mouth. Follow-up visits after visit 2 surgery will be conducted at week 1,2, 4,12 and 24 and in the long term after 1,3 and 5 years.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18 to 75 years of age, inclusive.
  • Subjects must have at least two teeth with buccal Miller Class I or II recession type defects, 3 mm deep and 3 mm wide on the same tooth in the contralateral quadrant of the same jaw
  • Defects should be similar in size and morphology
  • Teeth with root canals should be asymptomatic, completed at least 6 months prior
  • At least 1mm KT
  • Subjects with parafunctional habits must wear a bite guard to be included.

Exclusion criteria

  • Participation within the previous 30 days in other investigational clinical trials.
  • Class V restorations or abfractions that obliterate the CEJ.
  • Subjects whose teeth have extremely prominent root surfaces -greater than 2mm facially to the adjacent teeth measured at the level of the CEJ.
  • Systemic conditions that could influence wound healing or any other conditions that would preclude periodontal surgery.
  • Taking medications that compromise wound healing.
  • Acute infectious lesions in the areas intended for surgery.
  • Untreated moderate to severe periodontal disease.
  • Weekly or more frequent use of nicotine products within the past 6 months.
  • Females who are pregnant or lactating, or sexually active female subjects who are of childbearing potential and who are not using hormonal or barrier methods of birth control.
  • Subjects who require sedation in order to undergo surgery.
  • Molars, teeth with axial mobility or interproximal loss of attachment, or full coverage crowns or veneers do not qualify.

Treatment and study plan

Geistlich Fibro-Gide

Device

Surgical recession root coverage with coronally advanced flap in combination with Geistlich Fibro-Gide

Other names: Coronally advanced Flap (surgery/ procedure)

Connective Tissue Graft (CTG

Procedure

Surgical recession root coverage with coronally advanced flap in combination with CTG

Other names: Coronally advanced Flap (surgery/ procedure)

Primary outcomes

  1. Change in percent root coverage

    Time frame: 6 months post-treatment

    Change in percent root coverage compared to baseline

Secondary outcomes

  1. Safety Endpoints: number and frequency of (S)AEs over all and by organ class

    Time frame: 1, 2, 4, 7, 12 and 24 weeks and year 1,3 and 5 post treatment

    Assessment of (S)AEs starting at Visit 2, Surgery

  2. General Periodontal Examination (GPE)

    Time frame: baseline (day 0) and 6 months; 1, 3, 5 years post-treatment

    change of GPE at various visits compared to baseline, scoring codes 0-4

  3. Assessment of Wound Healing

    Time frame: 1, 2, 4, 12 weeks post-treatment

    Judgement of soft tissue wound healing after surgery at Visits 3-6; Primary complete wound closure? yes = complete/ no = dehiscence visible

  4. Assessment of Wound Healing

    Time frame: 1, 2, 4, 12 weeks post-treatment

    Judgement of soft tissue wound healing after surgery at Visits 3-6; if dehiscence visible, dehiscence size: lenght and width in mm

  5. Assessment of Wound Healing

    Time frame: 1, 2, 4, 12 weeks post-treatment

    Judgement of soft tissue wound healing after surgery at Visits 3-6; presence of Swelling (yes/ no),

  6. Overall Duration of Treatment Surgery

    Time frame: 2-6 hours at day of surgery

    Interval from surgery start until surgery end in Hours/Minutes

  7. Patient Reported Outcome (PRO) -Patient Diary: Discomfort

    Time frame: 7 days after surgery starting 1 day after surgery

    Post-Op PRO Discomfort Diary completed by Patients at home; scale 0-10, 0=no pain or discomfort at all, 10=as much as you can imagine,

  8. Patient Reported Outcome (PRO) -Questionnaire: Esthetics

    Time frame: 6 months, 1, 3, 5 years post-treatment

    Post-Op PRO questionnaire, Esthetics and overall satisfaction, patients will be asked by a 3rd party recorder, scale 0-10, 0=not satisfied at all with estehtic appearance, 10=completely satisfied,

  9. Patient Reported Outcome (PRO) -Questionnaire: for surgical preference

    Time frame: 1, 2, 4, 12 weeks, 6 months, 1, 3, 5 years post-treatment

    Post-Op PRO questionnaire, Surgival procedure Preference, patients will be asked by a 3rd party recorder, Overall which treatment did you prefer? A or B

  10. Safety endpoints: Concomitant Medication

    Time frame: 1, 2, 4, 12 weeks, 6 months, 1, 3, 5 years post-treatment

    Use of Concomitant medication Review: Type of concomitant Medication used.

Sponsors and collaborators

Lead sponsor

Geistlich Pharma AG

Industry

Collaborators

  • Medelis Inc.

Registry information

Official study title

A Prospective, Randomized, Controlled, Double-blind, Multi-center Study to Assess Non-inferiority of Geistlich Fibro-Gide® in Comparison to Connective Tissue Graft for the Treatment of Recession Defects

Acronym: GFG-US-REC

Important dates

Study start
2018
Primary completion
2020
Study completion
2020
First posted
Feb 7, 2020
Registry last updated
Aug 10, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.